73 days until earnings call
Interact to see
Advertisement
Advertisement
GINX vs GSK
GINX vs GSK Comparison
Open Charts GINX vs GSK
SGI Enhanced Global Income ETF
Price$29.26
Change+$0.14 (+0.48%)
Volume$5.3K
Net Assets83.4M
GINX vs GSK Comparison Chart in %
Loading...
Show more...
Show more...
View a ticker or compare two or three
VS
VS
GINX vs. GSK commentary
Aug 17, 2025
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GINX is a Buy and GSK is a Hold.
SUMMARIES
FUNDAMENTALS RATINGS
GSK: Fundamental Ratings
GSK | ||
|---|---|---|
OUTLOOK RATING 1..100 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 66 | |
SMR RATING 1..100 | 41 | |
PRICE GROWTH RATING 1..100 | 52 | |
P/E GROWTH RATING 1..100 | 27 | |
SEASONALITY SCORE 1..100 | 11 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TECHNICAL ANALYSIS
Technical Analysis
| GINX | GSK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 78% | 3 days ago 63% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 32% |
| Momentum ODDS (%) | 3 days ago 80% | 3 days ago 58% |
| MACD ODDS (%) | 3 days ago 87% | 3 days ago 67% |
| TrendWeek ODDS (%) | 3 days ago 87% | 3 days ago 59% |
| TrendMonth ODDS (%) | 3 days ago 82% | 3 days ago 53% |
| Advances ODDS (%) | 5 days ago 87% | 3 days ago 58% |
| Declines ODDS (%) | 17 days ago 60% | 12 days ago 54% |
| BollingerBands ODDS (%) | 3 days ago 75% | 3 days ago 42% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 44% |
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
Show more...
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MSVEX | 5.40 | 0.07 | +1.31% |
| Morgan Stanley Vitality Portfolio A | |||
| BRXUX | 16.30 | 0.03 | +0.18% |
| MFS Blended Research Intl Eq R4 | |||
| NCIGX | 32.82 | 0.05 | +0.15% |
| Nuveen International Value C | |||
| HQIRX | 21.63 | 0.02 | +0.09% |
| Hartford Equity Income R3 | |||
| MDGCX | 27.84 | -0.02 | -0.07% |
| BlackRock Advantage Global Investor A | |||
GINX and
Correlation & Price change
A.I.dvisor tells us that GINX and KMB have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GINX and KMB's prices will move in lockstep.
1D
1W
1M
1Q
6M
1Y
5Y
| Ticker / NAME | Correlation To GINX | 1D Price Change % | ||
|---|---|---|---|---|
| GINX | 100% | +0.47% | ||
| KMB - GINX | 21% Poorly correlated | -0.34% | ||
| GSK - GINX | 21% Poorly correlated | +1.44% | ||
| KO - GINX | 20% Poorly correlated | +0.53% | ||
| NVS - GINX | 20% Poorly correlated | +1.74% | ||
| RELX - GINX | 19% Poorly correlated | +0.57% | ||
More | ||||
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with AZN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then AZN could also see price increases.
1D
1W
1M
1Q
6M
1Y
5Y